The Comprehensive Adaptive Multisite Prevention of University Student Suicide (CAMPUS) trial aims to test more targeted, adaptive strategies to better treat the range of students experiencing suicidal ideation.

Duke University and North Carolina Central University (NCCU), a historically black college and university, celebrated a five-year partnership marked by extraordinary gains in cross-institutional educational opportunities, impactful research initiatives, and strong community outreach and support.

The UCLA-Duke National Center for Child Traumatic Stress (NCCTS) was awarded $40 million over five years to continue raising the standard of care and increasing access to services for children and their families across the U.S. who have experienced trauma.

The reason some people fail to recover their sense of smell after COVID-19 is linked to an ongoing immune assault on olfactory nerve cells and an associated decline in the number of those cells, a team of scientists led by Duke Health report.

Following the recent organizational changes at Twitter and concerns about how they may affect the platform, DCRI Chief Science & Digital Officer Eric Perakslis, PhD, offers insights for clinicians and researchers who use the platform to share their work.

Nadine Barrett, PhD, and Brian Southwell, PhD, have been appointed to serve on a National Academy of Science, Engineering and Math (NASEM) committee on Understanding and Addressing Misinformation about Science. 

Students from Duke’s Health Data Science (HDS) and AI Health Data Science Fellowship presented their work at the 2022 Duke AI Health Poster Showcase on Dec. 6.

Duke alum Leslie Graves has known about Duke’s mission to provide life-changing cancer care since she was a teenager. In October 2022, Graves received the William W. Shingleton Award, the highest honor given to friends of Duke Cancer Institute.

EDI Spotlight shines on Julius Wilder, MD, PhD, a gastroenterologist and hepatologist and Chair of the Department of Medicine’s Diversity, Equity, Inclusion, and Antiracism committee (DEIAR).

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between participants taking ivermectin and participants taking a placebo.